In particular, PIK3CA mutations appear to be associated with a favorable prognosis in early BC, while in metastatic HR+ and/or HER2+ carcinomas, they may be enriched in cases with unfavorable disease course and resistance to standard therapy schemes [14,15,16]. Here, ERBB2 is linked to breast cancer.